All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F14%3A43914658" target="_blank" >RIV/00023752:_____/14:43914658 - isvavai.cz</a>

  • Result on the web

    <a href="http://www.psychiatrist.com/JCP/article/Pages/2014/v75n04/v75n0411.aspx" target="_blank" >http://www.psychiatrist.com/JCP/article/Pages/2014/v75n04/v75n0411.aspx</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.4088/JCP.13m08433" target="_blank" >10.4088/JCP.13m08433</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

  • Original language description

    Agomelatine was efficacious in reducing symptoms in a short-term placebo-controlled trial in GAD and in preventing relapse in a longer term placebo-controlled study. An additional short-term placebo-controlled study is required by regulatory agencies toconfirm the efficacy of agomelatine in GAD. This 12-week, placebo-controlled, double-blind, randomized, parallel group, international, multicenter study was designed to confirm the efficacy of agomelatine 25-50 mg/d in the treatment of patients with a primary DSM-IV-TR diagnosis of GAD. The primary outcome measure was the (HARS) total score. Assay sensitivity was evaluated by including an escitalopram (10-20 mg/d) group. The study was undertaken in 45 clinical centers from April 2010 to July 2011. One hundred thirty-nine outpatients were included in the agomelatine group, 131 in the placebo group, and 142 in the escitalopram group. Agomelatine significantly reduced mean (SD) HARS total score (agomelatine-placebo difference: 4.71 [1.03],

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FL - Psychiatry, sexology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Clinical Psychiatry

  • ISSN

    0160-6689

  • e-ISSN

  • Volume of the periodical

    75

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    7

  • Pages from-to

    362-368

  • UT code for WoS article

    000336525700011

  • EID of the result in the Scopus database